Health
Bayer Kidney Drug Helps Treat Common Form of Heart Failure
This article is for subscribers only.
Bayer AG’s kidney drug Kerendia helped patients avoid complications from a common form of heart failure in a study, a boost for the company’s pharma division as it looks to overcome multiple challenges.
Kerendia reduced the relative risk of death and other serious events related to the form of heart failure, where pumping ability is reduced mildly at most, by 16%, according to a statement Sunday. The late-stage trial compared the therapy against a placebo in 6,000 adults suffering from the condition, which affects about 30 million people worldwide and lacks new treatments, the company said.